Detalhe da pesquisa
1.
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
Circulation
; 147(19): 1436-1443, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37009731
2.
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
Curr Atheroscler Rep
; 24(6): 427-434, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35386090
3.
Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study).
Circulation
; 135(22): 2133-2144, 2017 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275165
4.
[Familial combined hyperlipidemia: consensus document]. / Hiperlipidemia familiar combinada: documento de consenso.
Aten Primaria
; 46(8): 440-6, 2014 Oct.
Artigo
em Espanhol
| MEDLINE | ID: mdl-25034722
5.
Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study.
Circ Cardiovasc Imaging
; 17(1): e016206, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38205656
6.
Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.
Atherosclerosis
; 393: 117516, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38523000
7.
Prevalence of atherogenic dyslipidemia, related factors and level of lipid control in the general population of Galicia. GALIPEMIAS study. / Prevalencia de dislipemia aterogénica, factores relacionados y grado de control lipídico en la población general de Galicia. Estudio GALIPEMIAS.
Clin Investig Arterioscler
; 35(4): 178-184, 2023.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36717323
8.
Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
Eur J Prev Cardiol
; 30(4): 320-328, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36416136
9.
Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients.
J Clin Lipidol
; 16(5): 733-736, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35906178
10.
Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.
J Clin Lipidol
; 15(4): 584-592, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34052174
11.
Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry.
Rev Esp Cardiol (Engl Ed)
; 73(10): 828-834, 2020 Oct.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-32201274
12.
Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study.
J Clin Lipidol
; 13(6): 989-996, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31706904
13.
Coronary computed tomographic angiography findings and their therapeutic implications in asymptomatic patients with familial hypercholesterolemia. Lessons from the SAFEHEART study.
J Clin Lipidol
; 12(4): 948-957, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29753733
14.
Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry.
J Clin Lipidol
; 10(4): 953-961, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27578128
15.
[Familial combined hyperlipidemia: consensus document]. / Hiperlipidemia familiar combinada: documento de consenso.
Semergen
; 40(7): 374-80, 2014 Oct.
Artigo
em Espanhol
| MEDLINE | ID: mdl-25131181